Logo

People in the News: Jonathan Lord

Jul 10, 2013
Premium

Jonathan Lord has been named to Vigilant Biosciences' board of directors. Lord was previously CEO at Navigenics and currently serves as the chair of the board of directors of Dexcom, director at Stericycle, and on the advisory board of Serco, Anthello Health, and Third Rock Ventures.

Additionally, he is chief operating officer of the University of Miami's Miller School of Medicine and a professor of pathology.

Filed under

Clinical Sequencing
Sequencing
Diagnostics
Next-Generation Sequencing
Thermo Fisher Scientific
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.